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Glycoprotein (GP) IIb/IIIa inhibitors are beneficial in unstable angina/non–ST-segment
elevation myocardial infarction (UA/NSTEMI). In large trials, the GP IIb/IIIa inhibitors
tirofiban and eptifibatide were each found to reduce the risk of death or myocardial infarction
(MI) in these patients at 30 days. These agents appear to be of greatest benefit in patients with
a positive troponin at baseline, diabetes or ST-segment depression, recurrent angina, prior
aspirin use, or a Thrombolysis In Myocardial Infarction (TIMI) risk score 4. The Treat
angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative
Strategy (TACTICS) TIMI-18 trial was designed to compare the benefits of an early invasive
versus a conservative strategy in high-risk UA/NSTEMI patients treated with GP IIb/IIIa
inhibition. Patients were treated with tirofiban (for 48 h) plus aspirin and heparin and
randomized to either invasive therapy (coronary angiography and revascularization when
feasible) or conservative treatment (angiography only for patients with recurrent ischemia at
rest or a positive stress test). A significant reduction in death or MI was demonstrated at 30
days (p  0.02) and at 6 months (p  0.0498). Death, MI, or rehospitalization for an acute
coronary syndrome was also reduced with the invasive therapy at six months (p  0.025).
These results provide evidence to physicians that early GP IIb/IIIa inhibition in combination
with a prompt invasive approach should be used more widely in UA/NSTEMI patients,
particularly those at high risk. (J Am Coll Cardiol 2003;41:43S–48S) © 2003 by the
American College of Cardiology Foundation
With the elucidation of the role of platelets in the patho-
physiology of unstable angina (UA) and non–ST-segment
elevation myocardial infarction (NSTEMI), glycoprotein
(GP) IIb/IIIa receptor inhibitors have been identified and
developed as a promising new therapy for the reduction of
coronary thrombus and the improvement of outcomes.
Currently, the Food and Drug Administration in the U.S.
has approved three GP IIb/IIIa inhibitors for use as anti-
platelet agents: tirofiban, eptifibatide, and abciximab. The
influence of these novel agents on the management of
NSTEMI patients has recently been explored in several
large, randomized studies. In particular, insights into the
role of upstream GP IIb/IIIa inhibition in early invasive
versus early conservative strategies have recently been gained
from the Treat angina with Aggrastat and determine Cost
of Therapy with an Invasive or Conservative Strategy
(TACTICS) Thrombolysis In Myocardial Infarction
(TIMI)-18 trial.
In atherosclerotic disease, platelet aggregation occurs as
part of an interconnected pattern of plaque disruption, lipid
accumulation, mural thrombus formation, and lesion pro-
gression. When plaque rupture occurs, the subendothelial
protein matrix is disrupted, allowing platelet adhesion
molecules such as von Willebrand factor and collagen to
interact with circulating platelets. Platelet activation and
degranulation result. The GP IIb/IIIa receptors on the
platelet surfaces are upregulated and bind to circulating
fibrinogen and von Willebrand factor, causing cross-linking
and aggregation of the platelets. Antagonists of the GP
IIb/IIIa receptors can prevent binding of fibrinogen and von
Willebrand factor, reducing platelet aggregation and inhib-
iting platelet function.
Several large trials have shown GP IIb/IIIa inhibition to
be beneficial in UA/NSTEMI, either in patients treated
predominantly with medical management (1), early inter-
ventional management (2), or both (3–6). In the Platelet
Receptor inhibition for Ischemic Syndrome Management in
Patients Limited by Unstable Signs and Symptoms trial
(PRISM-PLUS), tirofiban plus heparin and aspirin signif-
icantly reduced the rate of death, myocardial infarction
(MI), or refractory ischemia at seven days compared with
heparin plus aspirin (3). Death or MI at 30 days was also
reduced significantly by 30%, from 11.9% to 8.7%, with the
reduction consistent across all management strategies (i.e.,
Please refer to the Trial Appendix at the back of this supplement for the complete list
of clinical trials.
From the TIMI Study Group, Cardiovascular Division, Brigham and Women’s
Hospital, Boston, Massachusetts. Dr. Cannon has received research support from
Bristol Myers-Squibb, Merck & Co., and Sanofi-Synthelabo. He has acted as a
consultant for Asahi Chemical Company, Bio-Technology General Corporation,
Pfizer Inc., Bayer Corporation and AstraZeneca Incorporated, Vertex, Medicines
Company, and Ortho-Clinical Diagnostics. He is also on the speaker’s bureau for
Aventis Pharmaceuticals, Bristol-Myers Squibb, Centoco, Eli Lilly, Merck & Co.,
Millennium, and Sanofi-Synthelabo. He has received honoraria for preparation of
educational materials from Centrocor, Eli Lilly, Excerpta Medica, Ingenix, Merck &
Co., NCME, and Discovery East.
Manuscript received May 7, 2002; accepted December 18, 2002.
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. doi:10.1016/S0735-1097(02)03018-8
medical therapy, 25% reduction; percutaneous transluminal
coronary angioplasty, 35% reduction; and coronary artery
bypass graft [CABG] surgery, 30% reduction) (Fig. 1)
(7). In the Platelet glycoprotein IIb/IIIa in Unstable
angina: Receptor Suppression Using Integrilin Therapy
(PURSUIT) trial, involving 10,948 patients, eptifibatide
also significantly reduced the rate of death or MI at 30 days
(4). In this trial, a greater benefit with eptifibatide was
observed in patients undergoing early angioplasty than with
other treatment strategies (4). A meta-analysis involving
over 30,000 patients found that treatment with a GP
IIb/IIIa inhibitor led to a 21% reduction in death or MI at
30 days (5,6).
Recently, an analysis of pooled data from PRISM-PLUS,
PURSUIT, and the Chimeric c7E3 AntiPlatelet Therapy in
Unstable REfractory angina (CAPTURE) trials, involving
12,296 patients, was carried out. A 34% relative reduction in
death or MI during 24 to 48 h of medical-management-
only (3.8% vs. 2.5%; p  0.001) was found among patients
who received a GP IIb/IIIa inhibitor (8). These findings
support the use of GP IIb/IIIa inhibition in the medical
management of patients with UA/NSTEMI for the pre-
vention of early events.
Of note, the Global Use of Strategies To Open Occluded
coronary arteries IV in Acute Coronary Syndromes
(GUSTO IV-ACS) trial found no benefit with abciximab
treatment in patients managed conservatively (9). Although
no clear explanation is apparent, one hypothesis is that the
dose of the infusion of abciximab may have been too low,
which led to sub-optimal levels of platelet inhibition. After
a 12-h infusion, the mean level of platelet inhibition was
found to be only 80% (indicating that half the patients had
levels80%) (Fig. 2) (10). After 24 to 48 h, the levels might
have fallen to even lower concentrations. By contrast, the
small-molecule GP IIb/IIIa inhibitors have documented
high, steady levels of platelet inhibition during the 48 to
72 h infusion periods (11). Accordingly, based on the
clinical trial data, the 2002 American College of Cardiolo-
gy/American Heart Association UA/NSTEMI Guidelines
recommend only tirofiban and eptifibatide for upstream use
in UA/NSTEMI (12).
Targeting high-risk patients. The benefit of GP IIb/IIIa
inhibition appears to be greatest in patients at higher risk, as
evidenced by those who have a positive troponin value at
baseline (Fig. 3) (13–16), diabetes (17,18), ST-segment
changes (3), recurrent angina (3,19), prior aspirin use (20),
or a TIMI risk score4 (21). In patients who are troponin-
positive, the benefit is an approximately 70% reduction in
death or MI (Fig. 3). No other intervention, not even
aspirin, can achieve such a marked benefit. Nonetheless, GP
IIb/IIIa inhibition appears to be very underused in current
practice, representing a missed opportunity for improving
outcomes in this high-risk population.
The mechanism for this benefit has emerged from recent
angiographic studies, including new data from the
TACTICS TIMI-18 trial. Patients with a positive troponin
were found to have more coronary thrombus, worse coro-
nary flow, and impaired myocardial perfusion (22,23).
Furthermore, angiographic analyses have shown that the use
of GP IIb/IIIa inhibitors, and longer infusion times for
these agents, can resolve thrombus and improve coronary
flow and myocardial perfusion more rapidly and completely
than aspirin and heparin alone (Fig. 4) (24–26).
TACTICS TIMI-18. Further validation of the benefit of
GP IIb/IIIa inhibition in the overall management of
UA/NSTEMI comes from the TACTICS TIMI-18 trial.
This trial was designed to re-examine the question of which
treatment strategy is optimal in the management of
UA/NSTEMI. In the TIMI IIIB trial, no difference was
seen between patients treated with an early invasive versus a
conservative strategy (27). An invasive strategy involved
routine coronary angiography 18 to 48 h after randomiza-
tion with revascularization (percutaneous coronary interven-
tion [PCI] or CABG) when feasible, based on anatomy.
The conservative strategy reserved angiography only for
patients with recurrent ischemia at rest or a positive stress
test.
Since the time of that trial, however, there have been two
major advances in cardiology that possibly affect the overall
efficacy and safety of an invasive approach: the advent of
coronary stenting and GP IIb/IIIa inhibition. The primary
hypothesis of the TACTICS TIMI-18 trial was that, with
the benefit of GP IIb/IIIa inhibition and coronary stenting,
Abbreviations and Acronyms
CABG  coronary artery bypass graft
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MI  myocardial infarction
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UA  unstable angina
Figure 1. PRISM-PLUS: 30-day death/MI by strategy. Benefit of up-
stream tirofiban stratified by the ultimate treatment strategy employed. CI
 confidence interval; CABG  coronary artery bypass graft; MI 
myocardial infarction; PRISM-PLUS  the Platelet Receptor inhibition
for ISchemic Management in Patients Limited to very Unstable Signs and
Symptoms; PTCA  percutaneous transluminal coronary angioplasty; Rx
 treatment. Data from Barr E, Thornton AR, Sax FL, Snapinn SM,
Theroux P. Benefit of tirofiban heparin therapy in unstable angina/non–
Q-wave myocardial infarction patients is observed regardless of interven-
tional treatment. Circulation 1998;98 Suppl I:I504. Reprinted with per-
mission from Lippincott, Williams and Wilkins.
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an early invasive strategy would be superior to a conservative
approach.
The TACTICS TIMI-18 trial enrolled patients (n 
2,220) with a typical history of UA/NSTEMI, with either
electrocardiographic changes, positive cardiac markers, or a
history of coronary disease. All were treated with aspirin,
heparin, and the GP IIb/IIIa inhibitor tirofiban for 48 h,
including 12 h after PCI. The primary hypothesis was
demonstrated. In patients treated with a GP IIb/IIIa inhib-
itor, the early invasive strategy led to a significant reduction
Figure 2. Level of platelet inhibition achieved after a 12-h bolus and infusion of abciximab. RPFA  rapid platelet function assay. Reprinted with
permission from Lippincott, Williams and Wilkins. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet
inhibition by standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999;100:
1977–82.
Figure 3. Benefit of glycoprotein IIb/IIIa inhibition in UA/NSTEMI based on positive or negative troponin levels. CAPTURE  c7E3 AntiPlatelet
Therapy in Unstable REfractory angina to standard treatment; PRISM  Platelet Receptor inhibition for ISchemic Management; TnI  troponin I;
TnT  troponin T. Data from Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation
to serum troponin T levels. N Engl J Med 1999;340:1623–9. Data from Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for
stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757–62. Reprinted with permission
from Elsevier Science.
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in the primary end point, death, MI, or rehospitalization for
an acute coronary syndrome at six months: 15.9% in the
early invasive group versus 19.4% in the conservatively
treated group (odds ratio, 0.78; p  0.025) (28). Death or
MI was also significantly reduced at 30 days (invasive group,
4.7%; conservative, 7.0%; p  0.02) and at 6 months (p 
0.0498).
When these data are compared with those from the four
previous randomized trials of invasive versus conservative
strategies (27,29–33), an interesting difference emerges. In
the trials without GP IIb/IIIa inhibition, the rate of MI
tends to be higher in the invasive group over the first two
weeks; this is consistent with an early hazard associated with
coronary interventions (34). By contrast, in TACTICS
TIMI-18, there was a significantly lower rate of MI over
the first weeks, an effect that probably results from the
well-documented protection afforded by GP IIb/IIIa inhi-
bition (6).
A direct comparison of TIMI IIIB versus TACTICS
TIMI-18 shows a consistently superior outcome with the
latter trial, as had been hypothesized (Fig. 5) (35). In
low-risk patients enrolled in TIMI IIIB, the incidence of
death, MI or rehospitalization after six months was signif-
icantly worse among patients randomized to the invasive
strategy arm, whereas in TACTICS TIMI-18, event rates
among low-risk patients were approximately equivalent for
both treatment strategies. For intermediate-risk patients,
the outcomes for invasive versus conservative approaches
were roughly equal in TIMI IIIB, whereas in TACTICS
TIMI-18, outcomes were significantly better with the in-
vasive approach. Finally, while there was a trend for im-
proved outcomes among high-risk patients treated inva-
sively in the TIMI IIIB trial, in TACTICS TIMI-18, a
dramatic 10% absolute reduction in events was found with
the invasive approach.
Risk stratification. As was observed with GP IIb/IIIa
inhibition, a significantly greater benefit was seen in patients
with positive troponin values compared with patients with
negative values (Fig. 3) (28). In patients with a troponin T
0.01 ng/ml (54% of the population) or in those with
troponin I 0.1 ng/ml (60% of the population), there was a
relative 39% risk reduction in the primary end point with
the invasive versus conservative strategy (p 0.001 in each).
Patients with a negative troponin had similar outcomes with
either strategy (36). The outcomes of death or non-fatal MI
followed the same pattern, with a significant reduction in
the invasive strategy group in patients with positive troponin
compared with no benefit in those with a negative troponin.
The same pattern of benefit was also seen in patients with
ST-segment changes on the baseline electrocardiogram, a
group that comprised 38% of the population. A TIMI risk
score 3 was also associated with increased benefit when
the invasive approach was used.
This study demonstrated that among patients with
UA/NSTEMI treated with the GP IIb/IIIa inhibitor,
tirofiban, an early invasive strategy was superior to a
conservative strategy in reducing major cardiac events at 30
days and 6 months. In addition, the absolute rate of death or
MI at 30 days in the invasive group, 4.7%, was the lowest
observed rate in any UA/NSTEMI trial to date (3,4,6,37).
Thus, this strategy of upstream GP IIb/IIIa inhibition with
tirofiban combined with an early invasive strategy leads to
excellent outcomes and could be considered the treatment of
choice for the majority of patients with UA/NSTEMI.
Summary. According to the current evidence from TAC-
TICS TIMI-18 and now, several other trials in UA/
NSTEMI (33,38–44), an early invasive strategy reduces the
risk of major cardiac events in patients with UA/NSTEMI
Figure 4. Preliminary results from the Percutaneous Coronary
Intervention-Treat Angina with Aggrastat and determine Cost of Therapy
with an Invasive or Conservative Strategy (PCI-TACTICS) substudy.
Longer duration of tirofiban was associated with improvements in myo-
cardial perfusion grade coronary flow and coronary thrombus grade. MV
multivariate; TIMI  Thrombolysis In Myocardial Infarction; TnT 
troponin T. Reprinted with permission from Lippincott, Williams and
Wilkins. Data from Gibson M, Murphy SA, Weisberg S, et al. Early
initiation of tirofiban therapy before percutaneous coronary intervention is
associated with improved flow and tissue level perfusion: a TACTICS
TIMI-18 substudy. Circulation 2001;104 Suppl II:II548–9.
Figure 5. Comparison of event rates in the Thrombolysis In Myocardial
Infarction (TIMI) IIIB versus Treat Angina with Aggrastat and determine
Cost of Therapy with an Invasive or Conservative Strategy (TACTICS)-
TIMI 18 trials stratified by TIMI risk score (TRS). ACS acute coronary
syndromes; CONS  conservative; Intermed  intermediate; INV 
invasive; MI  myocardial infarction; Rehosp  rehospitalization. Re-
printed with permission from Lippincott, Williams and Wilkins. Data
from Sabatine MS, Cannon CP, Murphy SA, DiBattiste PM, Demopou-
los LA, Braunwald E. Implications of upstream GP IIb/IIIa inhibition and
stenting in the invasive management of UA/NSTEMI: a comparison of
TIMI IIIB and TACTICS TIMI-18. Circulation 2001;104 Suppl II:
II549.
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more effectively than a conservative approach (38). This
benefit was observed in most patients studied, particularly
those at intermediate- or high-risk and notably in those
with positive troponin or ST-segment changes. By contrast,
lower-risk patients had similar outcomes with either strat-
egy, suggesting that either a conservative or invasive strategy
is appropriate for low-risk patients. The contribution of GP
IIb/IIIa inhibition is evidenced by the placebo-controlled
trials, in which upstream GP IIb/IIIa inhibition was initi-
ated upon admission. In these trials, reductions in death or
MI were demonstrated, particularly in troponin-positive
patients or those with TIMI risk score 3, regardless of
whether or not they ultimately underwent PCI. These
results provide encouragement to physicians for the wider
employment of early GP IIb/IIIa inhibition in combination
with an early invasive approach in intermediate- or high-
risk patients.
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